keyword
https://read.qxmd.com/read/38817994/systemic-therapy-for-pancreatic-neuroendocrine-tumors
#1
REVIEW
Viraj Lavingia, Shruti Gohel, Bhawna Sirohi
Pancreatic neuroendocrine tumors (PanNETs) account for approximately 2% of all pancreatic malignancies. Several systemic treatment options have been developed over the last four decades, ranging from cytotoxic chemotherapy and octreotide to newer targeted therapies like sunitinib, cabozantinib, and lenvatinib. Although surgery or liver-directed therapy remains cornerstone for management of metastatic PanNETs, however, they remain unfeasible in majority of cases. PanNETs behave differently than SI-NETs (small intestinal NET); the former is more aggressive and less responsive to somatostatin-based therapies...
May 2024: Indian Journal of Surgical Oncology
https://read.qxmd.com/read/38817298/neuroendocrine-carcinoma-of-the-common-hepatic-duct-coexisting-with-distal-cholangiocarcinoma-a-case-report-and-review-of-literature
#2
Fei Chen, Wei-Wei Li, Juan-Fen Mo, Min-Jie Chen, Su-Hang Wang, Shu-Ying Yang, Zheng-Wei Song
BACKGROUND: Neuroendocrine carcinoma (NEC) of the extrahepatic bile duct is very rare, and the treatment and prognosis are unclear. Herein, we report the case of a middle-aged female with primary large cell NEC (LCNEC) of the common hepatic duct combined with distal cholangiocarcinoma (dCCA). Additionally, after a review of the relevant literature, we summarize and compare mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) and pure NEC to provide a reference for selecting the appropriate treatment and predicting the prognosis of this rare disease...
May 27, 2024: World Journal of Gastrointestinal Surgery
https://read.qxmd.com/read/38814411/prolonged-response-to-dabrafenib-trametinib-in-grade-3-metastatic-pancreatic-neuroendocrine-tumor-net-g3-with-braf-v600e-mutation
#3
JOURNAL ARTICLE
Benjamin E Ueberroth, Christopher H Lieu, Robert W Lentz
PURPOSE: Treatment of metastatic pancreatic neuroendocrine tumors (pancNETs), particularly grade 2 (G2) and grade 3 (G3), often presents a dilemma in choosing from multiple similarly efficacious therapies. Data on targeted therapies for these tumor types is limited, and this report presents BRAF-targeted therapy as a therapeutic option for metastatic pancNET G3. METHODS: This is a case report of a patient with G3 pancNET metastatic to the liver, lung, lymph node, and scalp (soft tissue) treated with dabrafenib/trametinib (D/T) in the presence of a BRAF V600E mutation detected in tumor tissue...
May 30, 2024: Journal of Gastrointestinal Cancer
https://read.qxmd.com/read/38812165/-research-progress-in-treatment-of-chronic-prostatitis-chronic-pelvic-pain-syndrome-with-traditional-chinese-medicine
#4
REVIEW
Sheng-Long Li, Gang-Gang Lu, Yuan-Bo Zhao, Mei-Sheng Gong, Xu Ma, Yong-Qiang Zhao, Yun-Peng Jia, Yong-Lin Liang
Chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) is a common urological disease with complex etiology. The treatment effect of western medicine is not satisfactory, and the course of the disease is protracted, which brings great trouble to patients. Traditional Chinese medicine(TCM) has a variety of treatment methods based on syndrome differentiation and treatment, including internal treatment with TCM, acupuncture and massage, and other external treatment methods for comprehensive treatment, with significant effect...
May 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/38811222/ectopic-adrenocorticotropic-hormone-syndrome-due-to-pancreatic-neuroendocrine-carcinoma-a-case-report
#5
JOURNAL ARTICLE
Aya Kawanishi, Ryuzo Deguchi, Ayano Ito, Takashi Ueda, Kota Tsuruya, Yoshitaka Arase, Yoshihiro Shirataki, Toshiki Kodama, Masashi Morimachi, Tatehiro Kagawa
A 55-year-old woman presented to her primary care physician with facial and lower leg edema. After being referred to our hospital because of hypothyroidism and hypokalemia on blood tests, she also had elevated adrenocorticotropic hormone (ACTH) and cortisol levels, but a dexamethasone suppression test showed no cortisol suppression. Ectopic ACTH syndrome due to pancreatic neuroendocrine carcinoma (PNEC) was suspected. endoscopic ultrasound-guided fine-needle aspiration was performed, and a histopathological examination of the obtained specimen revealed multiple liver metastases of the PNEC...
May 30, 2024: Internal Medicine
https://read.qxmd.com/read/38807850/hypercalcemia-and-bone-metastasis-in-a-case-of-large-cell-neuroendocrine-carcinoma-with-unknown-primary
#6
Ekrem Yetiskul, Jordyn Salak, Fatema Arafa, Alaukika Agarwal, Amanda Matra, Muhammad Niazi, Marcel Odaimi
Large cell neuroendocrine carcinoma (LCNEC) constitutes a rare subset of highly undifferentiated malignancies known for their aggressive nature. Although these tumors commonly originate in the lungs and gastrointestinal tract, their potential occurrence is not restricted to specific anatomical sites, giving rise to a variety of symptoms. Notably, cases of neuroendocrine tumors (NETs) with an unidentified primary source exhibit a graver prognosis and shorter survival periods compared to those with clearly identified origins...
2024: Case Reports in Oncological Medicine
https://read.qxmd.com/read/38807765/primary-hepatic-neuroendocrine-neoplasms-imaging-characteristics-and-misdiagnosis-analysis
#7
JOURNAL ARTICLE
Xiu-Rong Yang, Ying-Li Li, Zi-Yan Li, Xiao-Ming Chai
OBJECTIVE: To analyze the CT and MR features of Primary hepatic neuroendocrine neoplasms (PHNENs) in order to enhance the diagnostic accuracy of this disease. METHODS: A retrospective analysis was conducted on patients diagnosed with hepatic neuroendocrine neoplasms, excluding other sites of origin through general examination and postoperative follow-up. The CT and MR signs were analyzed according to the 2018 version of Liver Imaging Reporting and Data System (LI-RADS), along with causes of misdiagnosis...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38797790/long-term-survival-outcomes-after-minimally-invasive-surgery-for-ileal-neuroendocrine-tumors
#8
JOURNAL ARTICLE
Akitada Yogo, Alan Paciorek, Yosuke Kasai, Farhana Moon, Kenzo Hirose, Carlos U Corvera, Emily K Bergsland, Eric K Nakakura
BACKGROUND: Ileal neuroendocrine tumors (i-NETs) are characterized by their multifocality and bulky mesenteric mass. Having shown that minimally invasive surgery (MIS) utilizing a hand-access port device has favorable short-term outcomes and achieves the goals of surgery for i-NETs, we sought to analyze long-term survival outcomes of MIS. METHODS: One hundred and sixty-eight patients who underwent resection of primary i-NETs at a single institution between January 2007 and February 2023 were retrospectively studied...
May 26, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38789854/-imaging-of-pancreatic-neuroendocrine-tumors
#9
REVIEW
Frank Berger, Maria Ingenerf, Christoph J Auernhammer, Clemens Cyran, Ricarda Ebner, Mathias Zacherl, Jens Ricke, Christine Schmid-Tannwald
BACKGROUND: Neuroendocrine tumors of the pancreas have a broad biological spectrum. The treatment decision is based on an optimal diagnosis with regard to the local findings and possible locoregional and distant metastases. In addition to purely morphologic imaging procedures, functional parameters are playing an increasingly important role in imaging. OBJECTIVES: Prerequisites for optimal imaging of the pancreas, technical principles are provided, and the advantages and disadvantages of common cross-sectional imaging techniques as well as clinical indications for these special imaging methods are discussed...
May 24, 2024: Radiologie (Heidelb)
https://read.qxmd.com/read/38783558/gastrointestinal-side-effects-of-somatostatin-analogs-in-neuroendocrine-tumors-a-focused-review
#10
REVIEW
Matteo Marasco, Elisabetta Dell'Unto, Alessandro Laviano, Davide Campana, Francesco Panzuto
Neuroendocrine tumors (NETs) are a group of well-differentiated heterogeneous neoplasms characterized by slow progression and distinct clinical and biological behavior. In the majority of patients with NET, first-line treatment is represented by somatostatin analogs (SSAs) that, despite being drugs with high tolerability (even at high doses) and providing to carcinoid symptoms control and anti-proliferative effects, may present some side effects, with potential impact on quality of life and nutritional status...
May 23, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38780689/aso-visual-abstract-value-of-surgical-cytoreduction-in-patients-with-small-intestinal-neuroendocrine-tumors-metastatic-to-the-liver-and-peritoneum
#11
JOURNAL ARTICLE
Hallbera Gudmundsdottir, Alessandro Fogliati, Travis E Grotz, Cornelius A Thiels, Susanne G Warner, Rory L Smoot, Mark J Truty, Michael L Kendrick, David M Nagorney, Thorvardur R Halfdanarson, Sean P Cleary, Patrick Starlinger
No abstract text is available yet for this article.
May 23, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38778465/triple-tumors-neuroendocrine-tumor-schwannoma-and-papillary-thyroid-carcinoma-with-brain-lesions-in-a-single-patient-demonstrating-avidity-on-68ga-dotatate-pet-ct-and-their-characterization-with-fdg-pet-ct-and-brain-mri
#12
JOURNAL ARTICLE
Rahul V Parghane, Sandip Basu
Neuroendocrine tumor (NET) typically spreads to the liver, lymph nodes, lungs, and skeleton. Brain metastasis in NET is uncommon. Therefore, each case of detected brain metastases in NET is crucial for the development of treatment guidelines for these types of tumors. We present a unique case of triple tumors (NET, papillary thyroid carcinoma, and schwannoma) in a single patient who presented with neurological symptoms and somatostatin receptor-avid T2 hyperintense multiple metastatic brain lesions from NET on 68Ga-DOTATATE-PET/CT scan and brain MRI...
May 23, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38767576/extraskeletal-ewing-sarcoma-of-the-gastrointestinal-and-hepatobiliary-tract-deceptive-immunophenotype-commonly-leads-to-misdiagnosis
#13
JOURNAL ARTICLE
Oyewale Shiyanbola, Recep Nigdelioglu, Deepti Dhall, Iván A González, Laura M Warmke, Shula Schechter, Won-Tak Choi, Shaomin Hu, Lysandra Voltaggio, Yujie Zhang, Tom Z Liang, Huaibin M Ko, Greg W Charville, Teri A Longacre
Ewing sarcoma (ES) is an uncommon mesenchymal neoplasm that typically develops as a bone mass, although up to 30% arise in extraskeletal sites. ES of the gastrointestinal (GI) and hepatobiliary tract is rare and may be misdiagnosed as other, more common neoplasms that occur in these sites. However, the correct classification of extraskeletal ES is important for timely clinical management and prognostication. We reviewed our experience of ES in the GI and hepatobiliary tract in order to further highlight the clinicopathologic features of these neoplasms and document the potential for misdiagnosis in this setting...
May 17, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38766687/sap-deletion-promotes-malignant-insulinoma-progression-by-inducing-cxcl12-secretion-from-cafs-via-the-cxcr4-p38-erk-signalling-pathway
#14
JOURNAL ARTICLE
Guangchun Jiang, Shuo Xu, Xiaobin Mai, Juan Tu, Le Wang, Lijing Wang, Yaping Zhan, Yan Wang, Qianqian Zhang, Lingyun Zheng, Jiangchao Li, Pei Tang, Cuiling Qi
Malignant insulinoma is an extremely rare type of functioning pancreatic neuroendocrine tumour with a high degree of malignancy and a high incidence of metastasis. However, it is still unclear how malignant insulinomas develop and metastasize. Serum amyloid P component (SAP), a member of the pentraxin protein family, is an acute-phase protein secreted by liver cells. The role of SAP in insulinoma and the related mechanism are still unknown. To determine the effect of SAP on insulinoma, we crossed Rip1-Tag2 mice, which spontaneously develop insulinoma, and SAP knockout (KO) mice to generate Rip1-Tag2;SAP-/- mice...
May 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38763794/endoscopic-submucosal-dissection-for-rectal-neuroendocrine-tumours-a-multicentric-retrospective-study
#15
JOURNAL ARTICLE
Alessandro Rimondi, Edward J Despott, Rocio Chacchi, Nikolaos Lazaridis, Deborah Costa, Ana-Maria Bucalau, Dalvinder Mandair, Mathieu Pioche, Jérome Rivory, Joao Santos-Antunes, Margarida Marques, Felipe Ramos-Zabala, Federico Barbaro, Pedro Pimentel-Nunes, Mario Dinis-Ribeiro, Eduardo Albeniz, Marcel Tantau, Cristiano Spada, Arnaud Lemmers, Martyn Caplin, Christos Toumpanakis, Alberto Murino
INTRODUCTION: Endoscopic Submucosal Dissection (ESD) has been reported as a feasible and effective treatment for Rectal Neuroendocrine Tumours (R-NETs). However, most of the experience on the topic comes from retrospective tertiary centre from Eastern Asia. Data on ESD for R-NETs in Western centres are lacking. MATERIALS AND METHODS: This is a retrospective study, including patients who underwent endoscopic resection of R-NETS by ESD between 2015 and 2020 in Western Centres...
May 18, 2024: Digestive and Liver Disease
https://read.qxmd.com/read/38761340/pathological-complete-response-with-folfirinox-therapy-for-recurrence-of-pancreatic-acinar-cell-carcinoma
#16
JOURNAL ARTICLE
Katsuhito Teramatsu, Nao Fujimori, Masatoshi Murakami, Sho Yasumori, Kazuhide Matsumoto, Kohei Nakata, Masafumi Nakamura, Yutaka Koga, Yoshinao Oda, Yoshihiro Ogawa
Pancreatic acinar cell carcinoma (PACC) is a very rare subtype of pancreatic cancer. Due to small number of patients, no standard chemotherapy protocol has been established. We experienced an extremely rare case of PACC with liver metastasis that showed a pathological complete response after modified FOLFIRINOX (mFFX) therapy. A 42-year-old man who underwent distal pancreatectomy for an 80 mm tumor at the pancreatic tail 3 years ago was referred to our hospital in September 2017 for the treatment of a recurrent liver tumor...
May 18, 2024: Clinical Journal of Gastroenterology
https://read.qxmd.com/read/38761204/-radiologically-guided-interventional-therapies-for-the-treatment-of-neuroendocrine-tumors
#17
REVIEW
C G Radosa, H Nebelung, F Schön, R T Hoffmann
BACKGROUND: The majority of patients with neuroendocrine tumors (NET) develop liver metastases during the course of the disease, significantly impacting prognosis and quality of life. CLINICAL ISSUE: Radiologically guided interventional therapies, such as thermal ablation, transarterial embolization (TAE)/chemoembolization (TACE), and selective internal radiotherapy (TARE), can play a crucial role in the treatment of metastatic NET. DATA: Due to the rarity of the disease, the majority of evidence is based on retrospective studies...
May 18, 2024: Radiologie (Heidelb)
https://read.qxmd.com/read/38756630/assessing-the-effectiveness-and-safety-of-surufatinib-versus-everolimus-or-sunitinib-in-advanced-neuroendocrine-neoplasms-insights-from-a-real-world-retrospective-cohort-study-using-propensity-score-and-inverse-probability-treatment-weighting-analysis
#18
JOURNAL ARTICLE
Linhui Zhu, Xuan Ye, Youjun She, Wensheng Liu, Kiyoshi Hasegawa, Roberta Elisa Rossi, Qiong Du, Qing Zhai
BACKGROUND: While surufatinib, sunitinib, and everolimus have shown efficacy for advanced neuroendocrine neoplasms (NENs) in randomized controlled trials (RCTs), direct comparisons in a real-world setting remain unexplored. This gap highlights the clinical need to understand their comparative effectiveness and safety within the diverse Chinese population. Addressing this, our study provides insights into the real-world performance of these therapies, aiming to inform treatment selection and improve patient outcomes...
April 30, 2024: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38748739/safety-and-efficacy-of-peptide-receptor-radionuclide-therapy-in-neuroendocrine-tumors-a-single-center-experience
#19
JOURNAL ARTICLE
Vineeth Sukrithan, Heather Armbruster, Sherise Rogers, Sherry Mori Vogt, Cassandra Grenade, Claire Verschraegen, Ye Zhou, Ashima Goyal, Mona Natwa, Akram Hussein, Hallie Barr, Dramane Konate, Rochelle Batdorf, Andrew Brown, Bonnie Williams, Songzhu Zhao, Lai Wei, Menglin Xu, Manisha H Shah, Bhavana Konda
Peptide receptor radionucleotide therapy (PRRT) with 177Lu-dotatate is widely used for the treatment of patients with neuroendocrine tumors (NETs). We analyzed data from 104 patients with NETs treated with 177Lu -dotatate at a US academic center between December 2017 and October 2020 to better understand patterns of long-term efficacy, safety, and toxicity in the real-world setting. 177Lu-dotatate (200 mCi) was administered every eight weeks for four doses. The most common sites of primary disease were small intestine NETs (n = 49, 47%), pancreatic NETs (n = 32, 31%), and lung NETs (n = 7, 7%)...
2024: PloS One
https://read.qxmd.com/read/38745508/defining-the-optimal-segmentation-method-for-measuring-somatostatin-receptor-expressing-tumor-volume-on-68ga-dotatate-positron-emission-tomography-computed-tomography-to-predict-prognosis-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors
#20
JOURNAL ARTICLE
Nuh Filizoglu, Salih Ozguven, Tugba Akin Telli, Tunc Ones, Fuat Dede, Halil T Turoglu, Tanju Y Erdil
OBJECTIVE: We aimed to compare different segmentation methods used to calculate prognostically valuable volumetric parameters, somatostatin receptor expressing tumor volume (SRETV), and total lesion somatostatin receptor expression (TLSRE), measured by 68Ga-DOTATATE PET/CT and to find the optimal segmentation method to predict prognosis. PATIENTS AND METHODS: Images of 34 patients diagnosed with gastroenteropancreatic neuroendocrine tumor (GEPNET) who underwent 68Ga-DOTATATE PET/CT imaging were reanalyzed...
May 15, 2024: Nuclear Medicine Communications
keyword
keyword
77982
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.